

From the INTERNATIONAL SEARCHING AUTHORITY

PCT

To:

China Patent Agent (H.K.) Ltd.
22/F, Great Eagle Centre
23 Harbour Road, Wanchai
Hong Kong Special Administrative Region,
P.R.China

NOTIFICATION OF TRANSMITTAL OF
THE INTERNATIONAL SEARCH REPORT
OR THE DECLARATION

(PCT Rule 44.1)

Date of mailing
(day/month/year)

24 DEC 1998 (24.12.98)

Applicant's or agent's file reference

FPCH981629P

FOR FURTHER ACTION See paragraphs 1 and 4 below

International application No.

PCT/CN98/00052

International Filing date
(day/month/year)

31 MAR 1998 (31.03.98)

Applicant

TONGHUA GANTECH BIOTECHNOLOGY LTD. et al

1. ☒ The applicant is hereby notified that the international search report has been established and is transmitted herewith.

Filing of amendments and statement under Article 19:

The applicant is entitled, if he so wishes, to amend the claims of the international application (see Rule 46):

When? The time limit for filing such amendments is normally 2 months from the date of transmittal of the international search report; however, for more details, see the notes on the accompanying sheet.

Where? Directly to the International Bureau of WIPO

34, Chemin des Colombettes

1211 Geneva 20, Switzerland

Facsimile No.: (41-22)740.14.35

For more detailed instructions, see the notes on the accompanying sheet.

2. ☐ The applicant is hereby notified that no international search report will be established and that the declaration under Article 17(2)(a) to that effect is transmitted herewith.
3. ☐ With regard to the protest against payment of (an) additional fee(s) under Rule 40.2, the applicant is notified that:
- ☐ the protest together with the decision thereon has been transmitted to the International Bureau together with the applicant's request to forward the texts of both the protest and the decision thereon to the designated Offices.
- ☐ no decision has been made yet on the protest; the applicant will be notified as soon as a decision is made.

4. **Further action(s):** The applicant is reminded of the following:

Shortly after 18 months from the priority date, the international application will be published by the International Bureau.

If the applicant wishes to avoid or postpone publication, a notice of withdrawal of the international application, or of the priority claim, must reach the International Bureau as provided in Rules 90bis.1 and 90bis.3, respectively, before the completion of the technical preparations for international publication.

Within 19 months from the priority date, a demand for international preliminary examination must be filed if the applicant wishes to postpone the entry into the national phase until 30 months from the priority date (in some Office even later).

Within 20 months from the priority date, the applicant must perform the prescribed acts for entry into the national phase before all designated Offices which have not been elected in the demand or in a later election within 19 months from the priority date or could not be elected because they are not bound by Chapter II.

Name and mailing address of the ISA/


The Chinese Patent Office
6, Xitucheng Road, Haidian District
Beijing 100088, P.R.China

Facsimile No. 86-10-62019451

Authorized officer

ZHOU LI

Telephone No. 86-10-62093058



These Notes are intended to give the basic instructions concerning the filing of amendments under Article 19. The Notes are based on the requirements of the Patent Cooperation Treaty, the Regulations and the Administrative Instructions under that Treaty. In case of discrepancy between these Notes and those requirements, the latter are applicable. For more detailed information, see also the *PCT Applicant's Guide*, a publication of WIPO.

In these Notes, "Article," "Rule" and "Section" refer to the provisions of the PCT, the PCT Regulations and the PCT Administrative Instructions, respectively.

INSTRUCTIONS CONCERNING AMENDMENTS UNDER ARTICLE 19

The applicant has, after having received the international search report, one opportunity to amend the claims of the international application. It should however be emphasized that, since all parts of the international application (claims, description and drawings) may be amended during the international preliminary examination procedure, there is usually no need to file amendments of the claims under Article 19 except where, e.g. the applicant wants the latter to be published for the purposes of provisional protection or has another reason for amending the claims before international publication. Furthermore, it should be emphasized that provisional protection is available in some states only.

What parts of the international application may be amended?

Under Article 19, only the claims may be amended.

During the international phase, the claims may also be amended (or further amended) under Article 34 before the International Preliminary Examining Authority. The description and drawings may only be amended under Article 34 before the International Preliminary Examining Authority.

Upon entry into the national phase, all parts of the international application may be amended under Article 28 or, where applicable, Article 41.

When? Within 2 months from the date of transmittal of the international search report or 16 months from the priority date, whichever time limit expires later. It should be noted, however, that the amendments will be considered as having been received on time if they are received by the International Bureau after the expiration of the applicable time limit but before the completion of the technical preparations for international publication (Rule 46.1).

Where not to file the amendments?

The amendments may only be filed with the International Bureau and not with the receiving Office of or the International Searching Authority (Rule 46.2).

Where a demand for international preliminary examination has been/is filed, see below.

How? Either by cancelling one or more entire claims, by adding one or more new claims or by amending the text of one or more of the claims as filed.

A replacement sheet must be submitted for each sheet of the claims which, on account of an amendment or amendments, differs from the sheet originally filed.

All the claims appearing on a replacement sheet must be numbered in Arabic numerals. Where a claim is cancelled, no renumbering of the other claims is required. In all cases where claims are renumbered, they must be renumbered consecutively (Administrative Instructions, Section 205(b)).

The amendments must be made in the language in which the international application is to be published.

What documents must/may accompany the amendments?

Letter (Section 205(B)):

The amendments must be submitted with a letter.

The letter will not be published with the international application and the amended claims. It should not be confused with the "Statement under Article 19(1)" (see below, under "Statement under Article 19(1)").

The letter must be in English or French, at the choice of the applicant. However, if the language of the international application is English, the letter must be in English; if the language of the international application is French, the letter must be in French.

The letter must indicate the differences between the claims as filed and the claims as amended. It must, in particular, indicate, in connection with each claim appearing in the international application (it being understood that identical indications concerning several claims may be grouped), whether

- (i) the claim is unchanged;
- (ii) the claim is cancelled;
- (iii) the claim is new;
- (iv) the claim replaces one or more claims as filed;
- (v) the claim is the result of the division of a claim as filed.

The following examples illustrate the manner in which amendments must be explained in the accompanying letter:

1. [where originally there were 48 claims and after amendment of some claims there are 51]:
"Claims 1 to 29,31,32,34,35,37 to 48 replaced by amended claims bearing the same numbers;
claims 30,33 and 36 unchanged; new claims 49 to 51 added."
2. [where originally there were 15 claims and after amendment of all claims there are 11]:
"Claims 1 to 15 replaced by amended claims 1 to 11."
3. [Where various kinds of amendments are made]:
"Claims 1-10 unchanged; claims 11 to 13,18 and 19 cancelled; claims 14,15 and 16 replaced by amended claim 14; claim 17 subdivided into amended claims 15,16 and 17, new claims 20 and 21 added."

"Statement under Article 19(1)"(Rule 46.4)

The amendments may be accompanied by a statement explaining the amendments and indicating any impact that such amendments might have on the description and the drawings (which cannot be amended under Article 19(1)).

The statement will be published with the international application and the amended claims.

It must be in the language in which the international application is to be published.

It must be brief, not exceeding 500 words if in English or if translated into English.

It should not be confused with and does not replace the letter indicating the differences between the claims as filed and as amended. It must be filed on a separate sheet and must be identified as such by a heading, preferably by using the words "Statement under Article 19(1)."

It may not contain any disparaging comments on the international search report or the relevance of citations contained in that report. Reference to citations, relevant to a given claim, contained in the international search report may be made only in connection with an amendment of that claim.

Consequence if a demand for international preliminary examination has already been filed

If, at the time of filing any amendments and any accompanying statement, under Article 19, a demand for international preliminary examination has already been submitted, the applicant must preferably, at the time of filing the amendments (and any statement) with the International Bureau, also file with the International Preliminary Examining Authority a copy of such amendments (and of any statement) and, where required, a translation of such amendments for the procedure before that Authority (see Rules 55.3(a) and 62.2, first sentence). For further information, see the Notes to the demand form (PCT/IPEA/401).

Consequence with regard to translation of the international application for entry into the national phase

The applicant's attention is drawn to the fact that, upon entry into the national phase, a translation of the claims as amended under Article 19 may have to be furnished to the designated/elected Offices, instead of, or in addition to, the translation of the claims as filed.

For further details on the requirements of each designated/elected Office, see the *PCT Applicant's Guide*, Volume II.

PCT

INTERNATIONAL SEARCH REPORT

(PCT Article 18 and Rules 43 and 44)

Applicant's or agent's file reference FPCH981629P	FOR FURTHER ACTION see Notification of Transmittal of International Search Report (Form PCT/ISA/220) as well as, where applicable, item 5 below.	
International application No. PCT/CN98/00052	International filing date(<i>day/month/year</i>) 31 MAR 1998 (31.03.98)	(Earliest) Priority Date(<i>day/month/year</i>)
Applicant TONGHUA GANTECH BIOTECHNOLOGY LTD. et al		

This international search report has been prepared by this international Search Authority and is transmitted to the applicant according to Article 18. A copy is being transmitted to the International Bureau.

This international search report consists of a total of 3 sheets.

☐ It is also accompanied by a copy of each art document cited in this report.

1. ☐ Certain claims were found unsearchable(See Box I)
2. ☐ Unity of invention is lacking(See Box II)
3. ☒ The international application contains disclosure of a nucleotide and/or amino acid sequence listing and the international search was carried out on the basis of the sequence listing
 - ☒ filed with the international application.
 - ☐ furnished by the applicant separately from the international application,
 - ☐ but not accompanied by a statement to the effect that it did not include matter going beyond the disclosure in the international application as filed.
 - ☐ transcribed by this Authority.
4. With regard to the title,
 - ☒ the text is approved as submitted by the applicant.
 - ☐ the text has been established by this Authority to read as follows:
5. With regard to the abstract ,
 - ☒ the text is approved as submitted by the applicant.
 - ☐ the text has been established, according to Rule 38.2(b), by this Authority as it appears in Box III. The applicant may, within one month from the date of mailing of this international search report, submit comments to this Authority.
6. The figure of the drawings to be published with the abstract is:

Figure No. _____	<input type="checkbox"/> as suggested by the applicant.	<input type="checkbox"/> None of the figures.
	<input checked="" type="checkbox"/> because the applicant failed to suggest a figure.	
	<input type="checkbox"/> because this figure better characterizes the invention.	

INTERNATIONAL SEARCH REPORT
Information on patent family members

International application No.
PCT/CN98/00052

Patent document cited in search report	Publication date	Patent family members	Publication date
WO-A-9620724	11-07-1996	ZA-A- 9500142	25-09-1996
		AU-A- 1550095	24-07-1996
		PL-A- 321039	24-11-1997
<hr/>			
WO-A-9718233	22-05-1997	AU-A- 7659696	05-06-1997

A. CLASSIFICATION OF SUBJECT MATTER

IPC⁶ C07K19/00,14/62,14/61,C12N15/62,C12N1/21(C12N1/21,C12R1:19)

According to International Patent Classification(IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched(classification system followed by classification symbols)

IPC⁶ C07K,C12N

Documentation searched other than minimum documentation to the extent that such documents are included in the field searched

CNPAT,Chinese Scientific and Technical Journals

Electronic data base consulted during the international search(name of data base and, where practicable, search terms used)
 GenBank CDS translations,PDB,SwissProt,SPupdate,PIR,WPI,DIALOG(files 5,155,357,358)
 (chimeric,chaperone,insulin,proinsulin,insulin precursor,
 growth hormone,somatotropin,fold,folding)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant claim No.
A	WO,A,96 20724 (BIO-TECHNOLOGY GENERAL CORP.) 11 July 1996 see the whole document	1-29,38-42, 44,46,47,50,51,62, 71-77
Y	Figure1,2,6,7, page 4 line 35-page 5 line 17, page 13 lines 14-26, Example 3	<u>30-37,43,45,</u> <u>48,49,52-61,63-70</u>
Y	WO,A,97 18233 (PHARMACIA & UPJOHN AB) 22 May 1997 see the whole document, especially page 4 line 14-page 6 line 8	30-37,43,45, 48,49,52-61,63-70



Further documents are listed in the continuation of Box C.



See patent family annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason(as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

16 December 1998 (16. 12. 98)

Date of mailing of the international search report

24 DEC 1998 (24. 12. 98)

Name and mailing address of the ISA/


The Chinese Patent Office
 6, Xitucheng Road, Haidian District,
 Beijing, 100088, China

Facsimile No. 86-10-62019451

Authorized officer

ZHOU LI

Telephone No. 86-10-62093058



PCT

REQUEST

The undersigned requests that the present international application be processed according to the Patent Cooperation Treaty.

International Application No.

International Filing Date

Name of receiving Office and "PCT International Application"

Applicant's or agent's file reference (if desired) (12 characters maximum) FPCH981629P

Box No. I TITLE OF INVENTION

CHIMERIC PROTEIN CONTAINING AN INTRAMOLECULAR CHAPERONE-LIKE SEQUENCE AND ITS APPLICATION TO INSULIN PRODUCTION

Box No. II APPLICANT

Name and address: (Family name followed by given name; for a legal entity, full official designation. The address must include postal code and name of country. The country of the address indicated in this Box is the applicant's State (i.e. country) of residence if no State of residence is indicated below)

TONGHUA GANTECH BIOTECHNOLOGY LTD.
Gantech Biotechnology, Dongbao Group, Tonghua City
Jilin Province, 134102 China

☐ This person is also inventor.

Telephone No. 0435-5858801

Facsimile No. 0435-5858585

Teleprinter No.

State (i.e. country) of nationality: CN

State (i.e. country) of residence: CN

This person is applicant for the purpose of:

☐

all designated States

☒

all designated States except the United States of America

☐

the United States of America only

☐

the States indicated in the Supplemental Box

Box No. III FURTHER APPLICANT(S) AND/OR (FURTHER) INVENTOR(S)

Name and address: (Family name followed by given name; for a legal entity, full official designation. The address must include postal code and name of country. The country of the address indicated in this Box is the applicant's State (i.e. country) of residence if no State of residence is indicated below)

GAN, Zhongru
Gantech Biotechnology, Dongbao Group, Tonghua City
Jilin Province, 134102 China

This person is:

☐ applicant only

☒ applicant and inventor

☐ inventor only (if this check-box is marked, do not fill in below)

State (i.e. country) of nationality: CN

State (i.e. country) of residence: CN

This person is applicant for the purpose of:

☐

all designated States

☐

all designated States except the United States of America

☒

the United States of America only

☐

the States indicated in the Supplemental Box

☒ Further applicants and/or (further) inventors are indicated on a continuation sheet.

Box No. IV AGENT OR COMMON REPRESENTATIVE: OR ADDRESS FOR CORRESPONDENCE

The person identified below is hereby/has been appointed to act on behalf of the applicants(s) before the competent International Authorities as:

☒ agent

☐ common representative

Name and address: (Family name followed by given name; for a legal entity, full official designation. The address must include postal code and name of country)

China Patent Agent (H.K.) Ltd.
22/F, Great Eagle Centre
23 Harbour Road, Wanchai
Hong Kong Special Administrative Region,
The People's Republic of China

Telephone No. (852)28284688

Facsimile No. (852)28271018

Teleprinter No.

☐ Mark this check-box where no agent or common representative is/has been appointed and the space above is used instead to indicate a special address to which correspondence should be sent.

Box No. V DESIGNATION OF STATES

The following designations are hereby made under Rule 4.9(a) (mark the applicable check-boxes; at least one must be marked):

Regional Patent

- ☒ **AP** ARIPO Patent: GH Ghana, GM Gambia, KE Kenya, LS Lesotho, MW Malawi, SD Sudan, SZ Swaziland, UG Uganda, ZW Zimbabwe, and any other State which is a Contracting State of the Harare Protocol and of the PCT
- ☒ **EA** Eurasian Patent: AM Armenia, AZ Azerbaijan, BY Belarus, KG Kyrgyzstan, KZ Kazakhstan, MD Republic of Moldova, RU Russian Federation, TJ Tajikistan, TM Turkmenistan, and any other State which is a Contracting State of the Eurasian Patent Convention and of the PCT
- ☒ **EP** European Patent: AT Austria, BE Belgium, CH and LI Switzerland and Liechtenstein, DE Germany, DK Denmark, ES Spain, FI Finland, FR France, GB United Kingdom, GR Greece, IE Ireland, IT Italy, LU Luxembourg, MC Monaco, NL Netherlands, PT Portugal, SE Sweden, and any other State which is a Contracting State of the European Patent Convention and of the PCT,
- ☒ **OA** OAPI Patent: BF Burkina Faso, BJ Benin, CF Central African Republic, CG Congo, CI Côte d'Ivoire, CM Cameroon, GA Gabon, GN Guinea, ML Mali, MR Mauritania, NE Niger, SN Senegal, TD Chad, TG Togo, and any other State which is a member State of OAPI and a Contracting State to the PCT (if other kind of protection or treatment desired, specify on the dotted line)

National Patent (if other kind of protection or treatment desired, specify on dotted line):

- | | |
|---|---|
| <input checked="" type="checkbox"/> AL Albania | <input checked="" type="checkbox"/> LT Lithuania |
| <input checked="" type="checkbox"/> AM Armenia | <input checked="" type="checkbox"/> LU Luxembourg |
| <input checked="" type="checkbox"/> AT Austria | <input checked="" type="checkbox"/> LV Latvia |
| <input checked="" type="checkbox"/> AU Australia | <input checked="" type="checkbox"/> MD Republic of Moldova |
| <input checked="" type="checkbox"/> AZ Azerbaijan | <input checked="" type="checkbox"/> MG Madagascar |
| <input checked="" type="checkbox"/> BA Bosnia and Herzegovina | <input checked="" type="checkbox"/> MK The former Yugoslav Republic of Macedonia |
| <input checked="" type="checkbox"/> BB Barbados | <input checked="" type="checkbox"/> MN Mongolia |
| <input checked="" type="checkbox"/> BG Bulgaria | <input checked="" type="checkbox"/> MW Malawi |
| <input checked="" type="checkbox"/> BR Brazil | <input checked="" type="checkbox"/> MX Mexico |
| <input checked="" type="checkbox"/> BY Belarus | <input checked="" type="checkbox"/> NO Norway |
| <input checked="" type="checkbox"/> CA Canada | <input checked="" type="checkbox"/> NZ New Zealand |
| <input checked="" type="checkbox"/> CH and LI Switzerland and Liechtenstein | <input checked="" type="checkbox"/> PL Poland |
| <input checked="" type="checkbox"/> CN China | <input checked="" type="checkbox"/> PT Portugal |
| <input checked="" type="checkbox"/> CU Cuba | <input checked="" type="checkbox"/> RO Romania |
| <input checked="" type="checkbox"/> CZ Czech Republic | <input checked="" type="checkbox"/> RU Russian Federation |
| <input checked="" type="checkbox"/> DE Germany | <input checked="" type="checkbox"/> SD Sudan |
| <input checked="" type="checkbox"/> DK Denmark | <input checked="" type="checkbox"/> SE Sweden |
| <input checked="" type="checkbox"/> EE Estonia | <input checked="" type="checkbox"/> SG Singapore |
| <input checked="" type="checkbox"/> ES Spain | <input checked="" type="checkbox"/> SI Slovenia |
| <input checked="" type="checkbox"/> FI Finland | <input checked="" type="checkbox"/> SK Slovakia |
| <input checked="" type="checkbox"/> GB United Kingdom | <input checked="" type="checkbox"/> SL Sierra Leone |
| <input checked="" type="checkbox"/> GE Georgia | <input checked="" type="checkbox"/> TJ Tajikistan |
| <input checked="" type="checkbox"/> GH Ghana | <input checked="" type="checkbox"/> TM Turkmenistan |
| <input checked="" type="checkbox"/> GM Gambia | <input checked="" type="checkbox"/> TR Turkey |
| <input checked="" type="checkbox"/> GW Guinea-Bissau | <input checked="" type="checkbox"/> TT Trinidad and Tobago |
| <input checked="" type="checkbox"/> HU Hungary | <input checked="" type="checkbox"/> UA Ukraine |
| <input checked="" type="checkbox"/> ID Indonesia | <input checked="" type="checkbox"/> UG Uganda |
| <input checked="" type="checkbox"/> IL Israel | <input checked="" type="checkbox"/> US United States of America |
| <input checked="" type="checkbox"/> IS Iceland | <input checked="" type="checkbox"/> UZ Uzbekistan |
| <input checked="" type="checkbox"/> JP Japan | <input checked="" type="checkbox"/> VN Viet Nam |
| <input checked="" type="checkbox"/> KE Kenya | <input checked="" type="checkbox"/> YU Yugoslavia |
| <input checked="" type="checkbox"/> KG Kyrgyzstan | <input checked="" type="checkbox"/> ZW Zimbabwe |
| <input checked="" type="checkbox"/> KP Democratic People's Republic of Korea | |
| <input checked="" type="checkbox"/> KR Republic of Korea | |
| <input checked="" type="checkbox"/> KZ Kazakhstan | |
| <input checked="" type="checkbox"/> LC Saint Lucia | |
| <input checked="" type="checkbox"/> LK Sri Lanka | |
| <input checked="" type="checkbox"/> LR Liberia | |
| <input checked="" type="checkbox"/> LS Lesotho | |

Check-boxes reserved for designating States (for the purposes of a national patent) which have become party to the PCT after issuance of this sheet:

☐

☐

☐

In addition to the designations made above, the applicant also makes under Rule 4.9(b) all designations which would be permitted under the PCT except the designation(s) of

The applicant declares that those additional designations are subject to confirmation and that any designation which is not confirmed before the expirations of 15 months from the priority date is to be regarded as withdrawn by the applicant at the expiration of that time limit. (Confirmation of a designation consists of the filing of a notice specifying that designation and the payment of the designation and confirmation fees. Confirmation must reach the receiving Office within the 15-month time limit)

Box No. VI

PRIORITY CLAIM

Further priority claims indicated in the Supplemental Box ☐

The priority of the following earlier application(s) is hereby claimed:

Country (in which, or for which, the application was filed)	Filing Date (day/month/year)	Application No.	Office of filing (Only for regional or international application)
item (1)			
item (2)			
item (3)			

Mark the following check-box if the certified copy of the earlier application is to be issued by the Office which for the purposes of the present international application is the receiving Office (a fee may be required):

☐ The receiving Office is hereby requested to prepare and transmit to the International Bureau a certified copy of the earlier application(s) identified above as item(s):

Box No. VII INTERNATIONAL SEARCHING AUTHORITY

Choice of International Searching Authority (ISA) (If two or more International Searching Authorities are competent to carry out the international search, indicate the Authority chosen; the two letter code may be used) **ISA/ CN**

Earlier search Fill in where a search (international, international-type or other) by the International Searching Authority has already been carried out or requested and the Authority is now requested to base the international search, to the extent possible, on the results of that earlier search. Identify such search or request either by reference to the relevant application (or the translation thereof) or by reference to the search request:

Country (or regional Office):

Date (day/month/year):

Number:

Box No. VIII CHECK LIST

This international application contains the following number of sheets:

1. request: 3 sheets
2. Description: 31 sheets
3. claims: 9 sheets
4. Abstract: 1 sheets
5. Drawings: 2 sheets

Total : 46 sheets

This international application is accompanied by the item(s) marked below:

1. ☐ separate signed power of attorney
2. ☐ copy of general power of attorney
3. ☐ statement explaining lack of signature
4. ☐ priority document(s) identified in Box No. VI as item(s):
5. ☒ fee calculation sheet
6. ☐ separate indications concerning deposited microorganisms
7. ☐ nucleotide and/or amino acid sequence listing (diskette)
8. ☐ other (specify):

Figure No. _____ of the drawings (if any) should accompany the abstract when it is published.

Box No. IX SIGNATURE OF APPLICANT OR AGENT

Next to each signature, indicate the name of the person signing and the capacity in which the person signs (if such capacity is not obvious from reading the request)

For receiving Office use only

1. Date of actual receipt of the purported international application:	2. Drawings: <input type="checkbox"/> received: <input type="checkbox"/> not received:
3. Corrected date of actual receipt due to later but timely received papers or drawings completing the purported international application:	
4. Date of timely receipt of the required corrections under PCT Article 11(2):	
5. International Searching Authority specified by the applicant: ISA/	
6. <input type="checkbox"/> Transmittal of search copy delayed until search fee is paid	

For International Bureau use only

Date of receipt of the record copy by the International Bureau:

PCT

FEE CALCULATION SHEET

Annex to the Request

For receiving Office use only

International application No.

Date stamp of the receiving Office

Applicant's or agent's
file reference

FPCH981629P

Applicant

TONGHUA GANTECH BIOTECHNOLOGY LTD.

CALCULATION OF PRESCRIBED FEES

1. TRANSMITTAL FEE	CNY 500	T
2. SEARCH FEE	CNY 800	S
International search to be carried out by <u>CN</u> (If two or more International Searching Authorities are competent in relation to the international application, indicate the name of the Authority which is chosen to carry out the international search.)		
3. INTERNATIONAL FEE		
Basic Fee		
The international application contains <u>46</u> sheets.		
first 30 sheets	CHF 650	b ₁
<u>16</u> remaining sheets	x <u>15</u> additional amount	CHF 240 b ₂
Add amounts entered at b ₁ and b ₂ and enter total at B	CHF 890	B
Designation Fees		
The international application contains _____ designations.		
number of designation fees	x	amount of designation fee payable(maximum 11)
Add amounts entered at B and D and enter total at I	CHF 890	I
(Applicants from certain States are entitled to a reduction of 75% of the international fee. Where the applicant is (or all applicants are) so entitled, the total to be entered at I is 25% of the sum of the amounts entered at B and D.)		
4. FEE FOR PRIORITY DOCUMENT		P
5. TOTAL FEES PAYABLE		
Add amounts entered at T,S,I and P, and enter total in the TOTAL box	CNY1300	
	CHF 890	
	TOTAL	

☒ The designation fees are not paid at this time.

MODE OF PAYMENT

<input checked="" type="checkbox"/> authorization to charge deposit account (see below)	<input type="checkbox"/> bank draft	<input type="checkbox"/> coupons
<input type="checkbox"/> cheque	<input type="checkbox"/> cash	<input type="checkbox"/> other(specify):
<input type="checkbox"/> postal money order	<input type="checkbox"/> revenue stamps	

DEPOSIT ACCOUNT AUTHORIZATION (this mode of payment may not be available at all receiving Offices)

The RO/ CN ☒ is hereby authorized to charge the total fees indicated above to my deposit account.

☒ is hereby authorized to charge any deficiency or credit any overpayment in the total fees indicated above to my deposit account

☐ is hereby authorized to charge the fee for preparation and transmittal of the priority document to the International Bureau of WIPO to my deposit account.

March 30, 1998

Deposit Account Number

Date(day/month/year)

Signature

(81) AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW; AP (GH GM KE LS MW SD SL SZ UG ZW); EA (AM AZ BY KG KZ MD RU TJ TM); EP (AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE); OA (BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG).

(51)⁶ C07K 16/00, 16/18, 16/44, C12Q 1/68, G01N 33/567

(11) WO 99/50300 (13) A1

(21) PCT/US99/06710

(22) 29 Mar/mar 1999 (29.03.1999)

(25) en (26) en

(30) 60/080,015 30 Mar/mar 1998 US (30.03.1998)

(30) 60/095,383 5 Aug/août 1998 US (05.08.1998)

(43) 7 Oct/oct 1999 (07.10.1999)

(54) • METHOD OF IDENTIFYING, DIAGNOSING AND TREATING SYN-
NUCLEIN POSITIVE NEURODEGEN-
ERATIVE DISORDERS

• METHODE D'IDENTIFICATION, DE
DIAGNOSTIC ET DE TRAITEMENT
DE TROUBLES NEURODEGENE-
RATIFS A NIVEAUX ELEVES DE
SYNUCLEINE

(63) US 60/080,015 (CIP)
30 Mar/mar 1998 (30.03.1998)
US 60/095,383 (CIP)
5 Aug/août 1998 (05.08.1998)

(71) THE TRUSTEES OF THE UNIVER-
SITY OF PENNSYLVANIA [US/US];
Center for Technology Transfer, Suite 300,
3700 Market Street, Philadelphia, PA 19104
(US).
(for all designated States except / pour tous
les États désignés sauf US)

(72, 75) TROJANOWSKI, John, Q. [US/US];
2005 Pine Street, Philadelphia, PA 19103
(US). LEE, Virginia, M.-Y. [US/US]; 2005
Pine Street, Philadelphia, PA 19103 (US).
IWATSUBO, Takeshi [JP/JP]; 4-39-2-401,
Houkomagome, Bunkyo-ku, Tokyo 113 (JP).

(74) LICATA, Jane, Massey et al. / etc.; Law
Offices of Jane Massey Licata, 66 E. Main
Street, Marlton, NJ 08053 (US).

(81) AU CA JP US; EP (AT BE CH CY DE DK
ES FI FR GB GR IE IT LU MC NL PT SE).

Published / Publiée : (c)

(51)⁶ C07K 16/10, C12N 5/20, G01N 33/576 //
C07K 14/18

(11) WO 99/50301 (13) A2

(21) PCT/EP99/02154

(22) 29 Mar/mar 1999 (29.03.1999)

(25) en (26) en

(30) 98870060.5 27 Mar/mar 1998 EP
(27.03.1998)

(43) 7 Oct/oct 1999 (07.10.1999)

(54) • EPITOPES IN VIRAL ENVELOPE
PROTEINS AND SPECIFIC ANTIBO-
DIES DIRECTED AGAINST THESE
EPITOPES: USE FOR DETECTION
OF HCV VIRAL ANTIGEN IN HOST
TISSUE

• EPITOPES DE PROTEINES EN-
VELOPPES VIRALES, ANTICORPS
SPECIFIQUES DE CES PROTEINES
ET LEUR UTILISATION DANS LA
DETECTION D'ANTIGENES DU VHC
DANS DES TISSUS HOTES

(71) INNOGENETICS N.V. [BE/BE]; Industrie-
park Zwijnaarde 7, P.O. Box 4, B-9052
Ghent (BE).
(for all designated States except / pour tous
les États désignés sauf US)

(72, 75) MAERTENS, Geert [BE/BE]; Zilver-
parrenstraat 64, B-8310 St. Kruis Brugge
(BE). DEPLA, Erik [BE/BE]; Burgstraat
58, B-9070 Destelbergen (BE). BUYSE,
Marie-Ange [BE/BE]; Burg. Edmond Ron-
sestraat 23, B-9820 Melsen (BE).

(74) JACOBS, Philippe; Innogenetics N.V.,
Industriepark Zwijnaarde 7, P.O. Box 4,
B-9052 Ghent (BE).

(81) AE AL AM AT AU AZ BA BB BG BR BY
CA CH CN CU CZ DE DK EE ES FI GB
GD GE GH GM HR HU ID IL IN IS JP KE
KG KP KR KZ LC LK LR LS LT LU LV
MD MG MK MN MW MX NO NZ PL PT
RO RU SD SE SG SI SK SL TJ TM TR TT
UA UG US UZ VN YU ZA ZW; AP (GH
GM KE LS MW SD SL SZ UG ZW); EA
(AM AZ BY KG KZ MD RU TJ TM); EP
(AT BE CH CY DE DK ES FI FR GB GR
IE IT LU MC NL PT SE); OA (BF BJ CF
CG CI CM GA GN GW ML MR NE SN TD
TG).

(51)⁶ C07K 19/00, 14/62, 14/61, C12N 15/62,
I/21 // (C12N 1/21, C12R 1:19)

(11) WO 99/50302 (13) A1

(21) PCT/CN98/00052

(22) 31 Mar/mar 1998 (31.03.1998)

(25) en (26) en

(43) 7 Oct/oct 1999 (07.10.1999)

(54) • CHIMERIC PROTEIN CONTAIN-
ING AN INTRAMOLECULAR
CHAPERONE-LIKE SEQUENCE AND
ITS APPLICATION TO INSULIN PRO-
DUCTION

• PROTEINE CHIMERE CONTENANT
UNE SEQUENCE DE TYPE CHA-
PERON INTRAMOLECULAIRE ET
SON APPLICATION DANS LA PRO-
DUCTION D'INSULINE

(71) TONGHUA GANTECH BIO-
TECHNOLOGY LTD. [CN/CN]; Gantech
Biotechnology, Dongbao Group, Tonghua
City, Jilin Province 134102 (CN).
(for all designated States except / pour tous
les États désignés sauf US)

(72, 75) GAN, Zhongru [CN/CN]; Gantech Bio-
technology, Dongbao Group, Tonghua City,
Jilin Province 134102 (CN).

(74) CHINA PATENT AGENT (H.K.) LTD.;
22/F, Great Eagle Centre, 23 Harbour Road,
Wanchai, Special Administrative Region
Hong Kong (CN).

(81) AL AM AT AU AZ BA BB BG BR BY CA
CH CN CU CZ DE DK EE ES FI GB GE
GH GM GW HU ID IL IS JP KE KG KP
KR KZ LC LK LR LS LT LU LV MD MG
MK MN MW MX NO NZ PL PT RO RU
SD SE SG SI SK SL TJ TM TR TT UA UG
US UZ VN YU ZW; AP (GH GM KE LS
MW SD SZ UG ZW); EA (AM AZ BY KG
KZ MD RU TJ TM); EP (AT BE CH DE
DK ES FI FR GB GR IE IT LU MC NL PT
SE); OA (BF BJ CF CG CI CM GA GN ML
MR NE SN TD TG).

(51)⁶ C07K 19/00, A61K 39/385, 38/17, 39/00,
39/21, 39/29, C07K 14/155, 14/02

(11) WO 99/50303 (13) A2

(21) PCT/US99/07236

(22) 1 Apr/avr 1999 (01.04.1999)

(25) en (26) en

(30) 09/053,301 1 Apr/avr 1998 US
(01.04.1998)

(30) Not furnished / 31 Mar/mar 1999 US
non communiqué (31.03.1999)

(43) 7 Oct/oct 1999 (07.10.1999)

(54) • IMMUNE RESPONSE MODULATOR
ALPHA-2 MACROGLOBULIN COM-
PLEX

• COMPLEXE D'ALPHA-2 MACRO-
GLOBULINE MODULATEUR DE LA
REPOSE IMMUNITAIRE

(63) US 09/053,301 (CIP)
1 Apr/avr 1999 (01.04.1999)

(71) DUKE UNIVERSITY [US/US]; 230 North
Building, Research Drive, Durham, NC
27708 (US).
(for all designated States except / pour tous
les États désignés sauf US)

(72, 75) PIZZO, Salvatore, V. [US/US]; 10009
Stallion Way, Bahama, NC 27503 (US).
GRON, Hanne [DK/US]; Apartment H7,
6123 Farrington Road, Chapel Hill, NC
27514 (US).

(74) YAMIN, Michael, A. et al. / etc.; Klaub-
er & Jackson, 411 Hackensack Avenue, Ha-
ckensack, NJ 07601 (US).

(81) AE AL AM AT AU AZ BA BB BG BR BY
CA CH CN CU CZ DE DK EE ES FI GB
GD GE GH GM HR HU ID IL IN IS JP KE
KG KP KR KZ LC LK LR LS LT LU LV
MD MG MK MN MW MX NO NZ PL PT
RO RU SD SE SG SI SK SL TJ TM TR TT
UA UG US UZ VN YU ZA ZW; AP (GH
GM KE LS MW SD SL SZ UG ZW); EA
(AM AZ BY KG KZ MD RU TJ TM); EP
(AT BE CH CY DE DK ES FI FR GB GR
IE IT LU MC NL PT SE); OA (BF BJ CF
CG CI CM GA GN GW ML MR NE SN TD
TG).